Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Accured Expenses (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Change in Accured Expenses for 9 consecutive years, with $13.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 185.7% to $13.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.5 million, a 479.82% increase, with the full-year FY2025 number at $48.5 million, up 479.82% from a year prior.
  • Change in Accured Expenses was $13.9 million for Q4 2025 at Akebia Therapeutics, down from $15.8 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $30.8 million in Q3 2021 to a low of -$37.2 million in Q4 2021.
  • A 5-year average of -$1.7 million and a median of $1.6 million in 2024 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: crashed 440.04% in 2023, then soared 2984.2% in 2025.
  • Akebia Therapeutics' Change in Accured Expenses stood at -$37.2 million in 2021, then surged by 55.7% to -$16.5 million in 2022, then soared by 122.55% to $3.7 million in 2023, then skyrocketed by 31.26% to $4.9 million in 2024, then surged by 185.7% to $13.9 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Change in Accured Expenses are $13.9 million (Q4 2025), $15.8 million (Q3 2025), and $16.0 million (Q2 2025).